May 2026
đź“Ł VC round data is live. Check it out!
Largest Biopharmaceuticals Public Companies in Sweden
Benchmark revenue and EBITDA valuation multiples for public comps like
Sobi, Camurus, BioArctic, Swedencare and Vicore Pharma Holding.
 | Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo). | $48 | +52% | $17B | $19B | 5.9x | 14.9x | ||
| Camurus AB is a research and development-focused pharmaceutical company. It develops pharmaceuticals for the treatment of serious and chronic diseases such as opioid addiction, pain, cancer, and endocrine diseases. The Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company's product pipeline includes CAM2029, CAM4072 and CAM2043. | $58 | +5% | $3B | $3B | 11.9x | 29.3x | ||
| BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America. | $36 | +83% | $3B | $3B | 13.3x | 21.6x | ||
| Swedencare AB specializes in pet healthcare. It develops, manufactures partly in its factories, markets, and sells products in the fast-growing market of healthcare products for cats, dogs, and horses. The group has an extensive portfolio of brands and products in various therapy areas, including Animal Pharmaceuticals, Nutravet, NutriScience, Pet MD, Stratford, VetWELL, ProDen PlaqueOff, Rx Vitamins, Riley’s, NaturVet, Pet Organics, Overby Farm, Vet Classics, and Innovet’s brands. Its products are sold to veterinarians, pet stores, and online through a distribution network comprising various subsidiaries and an international network of retailers. The group's operating segments include North America, which generates maximum revenue, Europe, and Production. | $3 | -33% | $464M | $642M | 2.1x | 11.4x | ||
| Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2b development for IPF. The company also has an investigational medical device in clinical development, namely, Almee, which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis. | $1 | +49% | $373M | $259M | 632.5x | (7.1x) | ||
| Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales. | $4 | +48% | $369M | $419M | 16.8x | (10.5x) | ||
| Probi AB is engaged in probiotic research and development, manufacturing and sales of effective and well-documented probiotics. Its research relates to living microorganisms with scientific health benefits. The main fields of research are gut health, immune system and nutrient absorption, iron absorption, bone health and stress and recovery. It operates in Consumer Healthcare (CHC) and Functional Food (FF). The company operates in United States, Americas, excluding the United States , Sweden, EMEA, excluding Sweden, and APAC. The company's business is divided into three operating segments. These segments are based on a geographical division and consist of the regions Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia and the Pacific). | $32 | -- | $362M | $338M | — | — | ||
| Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. | $1 | +85% | $314M | $306M | 42.3x | (9.8x) | ||
| Flerie AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The portfolio of the company includes Immuno-Oncology, metabolic diseases, and biologics development and manufacturing organizations. | $3 | -47% | $242M | $179M | — | (2.2x) | ||
| BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin’s lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers. | $3 | -19% | $203M | $155M | 6.2x | (4.6x) | ||
| Cereno Scientific AB is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The company's program, CS1, is a phase two dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. Cereno Scientificalso evaluates the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation, and high blood pressure in the pulmonary circulation system. | $1 | -44% | $194M | $199M | — | (25.6x) | ||
| Karolinska Development AB is a life science investment company. It is focused on identifying breakthrough medical innovations in the Nordic region. It selects commercially attractive medical innovations, develops innovations to the stage where the return on investment can be achieved, and commercializes the innovations through the sales of companies or out-licensing of products. The company focused on profiles namely Aprea Therapeutics; Modus Therapeutics; BioArctic; Umecrine Cognition; and OssDsign. | $0 | -- | $163M | $43M | — | — | ||
| Hamlet BioPharma AB publ is a pharmaceutical company engaged in the research and development of drugs used for curing cancer. | $1 | +82% | $148M | $147M | — | (30.6x) | ||
| XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and other. | $3 | -22% | $123M | $126M | 174.6x | (7.8x) | ||
| Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also has various out-licensed projects, such as MIV-701, birinapant, USP-1/TNG348, USP-7, and MBLI/MET-X, as well as two other drug projects, remetinostat and MIV-711, in the clinical development phase. Geographically, it generates its maximum revenue from Europe and other regions. | $0 | +11% | $116M | $104M | 106.9x | (16.3x) | ||
| EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden. | $3 | -68% | $85M | $128M | 2.7x | 15.1x | ||
| Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, as well as its antibody platform CANxx. | $0 | +118% | $81M | $75M | 2.1x | 4.3x | ||
| SynAct Pharma AB is a clinical-stage biotech company focused on resolving inflammation through selective activation of the melanocortin system. The company has a platform technology based on a new class of drug candidates that target acute exacerbations in chronic inflammatory diseases with the primary aim of stimulating natural healing mechanisms. AP1189, the company's lead drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure. | $1 | -7% | $78M | $73M | — | (5.8x) | ||
| Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs. | $6 | -7% | $78M | $63M | — | (8.7x) | ||
| Orexo AB has operations in Sweden and the United States. Operations are monitored and presented in the segments USA Pharma, Digital Therapeutics (DTx), and HQ & Pipeline. The majority is from the USA Pharma segment. Geographically, the majority is derived from the United States. USA Pharma includes the commercialization of fully owned pharmaceuticals in the United States market. Digital Therapeutics include the commercialization of Orexo’s groundbreaking evidence-based digital therapeutics, mainly in the United States market, which is in an early development stage. HQ &Pipeline includes the Development of pharmaceuticals performed at Orexo’s headquarters in Uppsala, Sweden. | $2 | +36% | $75M | $34M | 11.8x | (1.1x) | ||
| Nanexa AB is a pharmaceutical company developing injectable drug products based on the proprietary drug delivery system PharmaShell - the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. The company develops its products and also has collaboration agreements with several pharma companies, among others AstraZeneca. Geographically, the company derives maximum revenue from Nordic countries. | $0 | +78% | $72M | $64M | 16.6x | 144.0x | ||
| Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and, in particular, multiple myeloma. | $0 | +16% | $71M | $63M | 8.0x | (2.6x) | ||
| Cinclus Pharma Holding AB is a clinical stage pharmaceutical company developing a drug for the treatment of erosive gastroesophageal reflux diseases, and a dual therapy treatment with an antibiotic targeting Helicobacter pylori which is a bacteria that occurs in the gastric and duodenal mucosa. The Company’s main target population is patients suffering from severe eGERD, where there is a lack of satisfactory treatment options. | $1 | -20% | $60M | $15M | 2.3x | (0.8x) | ||
| Dicot Pharma AB is developing a modern potency medicine that will treat erectile dysfunction and premature ejaculation better than existing preparations. The company's drug candidate LIB-01 has a longer duration of action and fewer side effects and also used in the treatment of erectile dysfunction and premature ejaculation. | $0 | -60% | $55M | $49M | — | (5.7x) | ||
| Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company’s main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world. | $1 | +11% | $53M | $29M | 19.3x | (12.2x) | ||
| Corline Biomedical AB offers customers in the medical technology industry and regenerative medicine as well as transplant clinics products to manage immune thrombosis. The company offers a proprietary surface treatment technology, Corline Heparin Surface (CHS), which can be used in combination with all commonly used implant materials such as polymers (plastics) and various metals, but also for equipment where blood circulation occurs outside the body. | $2 | +81% | $51M | $48M | 55.7x | (30.3x) | ||
| Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development. | $0 | -22% | $47M | $43M | — | (5.3x) | ||
| Intervacc AB is a biotechnology company. It develops new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care. The company through its subsidiary focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses on the Swedish market. | $0 | +18% | $45M | $28M | 12.5x | (5.3x) | ||
| Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate. | $0 | +707% | $40M | $28M | 1.5x | 2.6x | ||
| Mendus AB is a clinical-level biopharmaceutical company based on the company's allogeneic dendritic cell biology focused on the development of immunotherapies that address tumor recurrence and hard-to-treat established tumors. Its operations consist of research and development for pharmaceuticals. Company Pipeline includes: Vididencel, Ilixadencel, Preclinical. | $1 | +6% | $37M | $31M | 69.5x | (2.8x) | ||
| Lipum AB is a clinical-stage biopharmaceutical company specializing in the discovery and development of a novel treatment for chronic inflammatory diseases. The candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule (BSSL) of the immune system. The development is supported by solid pre-clinical data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. | $2 | -6% | $32M | $32M | — | — | ||
| Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. Xbrane’s product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. | $1 | -59% | $26M | $25M | 1.5x | (21.3x) | ||
| Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. Its products are used to increase efficacy and reduce the side effects of antimetabolite cancer treatment. | $0 | -22% | $25M | $13M | — | (2.2x) | ||
| Xintela AB is a biomedical company that develops stem cell-based treatments with a focus on osteoarthritis and hard-to-heal leg wounds as well as, through the wholly-owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancers such as triple-negative breast cancer and the brain tumor glioblastoma. | $0 | -32% | $24M | $24M | 93.7x | (4.8x) | ||
| Klaria Pharma Holding AB is a Swedish pharmaceutical company that develops rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Its patented drug delivery platform consists of an alginate-based polymer film that enables the absorption of a product’s active substance through the oral mucosa. | $0 | +90% | $21M | $23M | 24.2x | (15.5x) | ||
| Active Biotech AB focuses on the research and development of pharmaceuticals products within medical areas including neurodegenerative diseases, autoimmune/inflammatory disease and various forms of cancer. Its project portfolio contains both small molecules that are orally active immunomodulatory agents and antibody based immunotherapy. | $0 | -73% | $20M | $13M | — | (3.5x) | ||
| DexTech Medical AB is a Swedish research company specializing in drug development for urological oncology, with a prominent focus on prostate cancer. The company develops drug candidates using a proprietary carbohydrate platform, advancing treatments aimed at castration-resistant prostate cancer and related conditions. Its operations center on research, development, and licensing of these drug candidates. It has four drug candidates: OsteoDex, SomaDex, PSMA-binding conjugates, and GuaDex. | $1 | +87% | $19M | $18M | — | (154.5x) | ||
| AcuCort AB is an innovative biotechnology company that identifies, develops and commercializes smart drugs that meet the patient’s needs for a user-friendly and effective treatment. | $0 | -22% | $17M | $15M | 193.9x | (7.9x) | ||
| Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments. | $2 | +7064% | $17M | $18M | — | (5.3x) | ||
| AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drugs within its three research platforms NeuroRestore, Alzstatin, and Painless. The company's drug candidates include; ACD440, which is in the clinical development phase for the treatment of neuropathic pain, ACD856, ACD857, ACD679, and ACD680 for the treatment of Alzheimer's disease, and ACD137 for the treatments of severe pain in conditions such as osteoarthritis. | $0 | -53% | $17M | $14M | — | (2.8x) | ||
| Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company’s activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65. | $0 | -87% | $17M | $6M | 421.4x | (0.3x) | ||
| Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. The company's product portfolio consists of four drug candidates, two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to a universal CAR T-cell technology platform, iTANK (ELC-001), compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors. | $0 | -52% | $16M | $14M | — | (7.6x) | ||
| Opsy Holding AB is a Swedish tech company that develops solutions at the intersection of medicine and insurance. The group assures, optimizes, and modernizes handling illnesses, accidents, and personal injuries. It's platform OpsyOne, develop and automates claims settlement processes to increase precision, transparency, and efficiency. | $1 | +108% | $16M | $16M | 22.2x | (12.4x) | ||
| NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants. | $0 | +17% | $15M | $12M | 10.1x | (3.6x) | ||
| Abera Bioscience AB is a platform and vaccine development company based on research in the medical, molecular, and microbiological fields. The company's mission is to develop vaccine candidates based on its novel vaccine delivery platform to late pre-clinical or early clinical phase. | $1 | -10% | $15M | $12M | — | (10.6x) | ||
| Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. Its drug candidate mitazalimab, is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 18-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. | $0 | -90% | $14M | $14M | 256.1x | (25.7x) | ||
| IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company’s current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials. | $0 | -82% | $11M | $9M | 1.3x | (1.0x) | ||
| OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches. | $1 | +41% | $11M | $12M | 41.3x | (7.0x) | ||
| Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion. | $1 | -61% | $10M | $8M | — | (2.1x) | ||
| Coegin Pharma AB is a Swedish biotechnology company with projects in hair growth, skin pigmentation, heart attacks, and leukemia. Its project portfolio builds on three distinct, patented technology platforms: the FOL peptide technology, the pigmentation peptide technology, and the cPLA2 alpha technology. The company's project portfolio consists of both cosmetic dermatology and drug development projects. Currently, it is focused on the cosmetic dermatology projects, which include the NPP-4 project for skin pigmentation and the Follicopeptide project for hair growth. In addition, the company's project portfolio also includes three drug development projects: FOL026, for the treatment of myocardial infarction (heart attack); AVX420 for the treatment of leukemia; and AVX001. | $0 | +3% | $10M | $9M | 1058.9x | (4.8x) | ||
| Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through the previous detection of tumors and metastases. The Tumorad products focus on the development of a completely new form of radionuclide therapy for tumor-selective radiation therapy of cancer. The company's development projects are based on a platform of polymeric materials with various properties for the precise diagnosis and treatment of life-threatening and debilitating diseases. | $0 | -18% | $9M | $6M | 130.4x | (2.2x) | ||
| Magle Chemoswed Holding AB is a contract development and manufacturing organization that serves companies in the pharmaceutical and medical device industry on a contract basis. It provides comprehensive services from product development through product manufacturing. The company's products portfolio includes Warfarin sodium, Melperone hydrochloride, Isradipine, Amantadine sulfate, and Benserazide hydrochloride. | $0 | -86% | $8M | $44M | 1.5x | (16.9x) | ||
| Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is engaged in the development of a specific oligomer-directed vaccine (ALZ-101), and ALZ-201 which is a monoclonal antibody that is specific for the toxic AB oligomers. The products of the company are in the clinical and preclinical stages of development as a therapeutic vaccine for the treatment of Alzheimer’s. | $0 | -72% | $8M | $8M | — | (3.0x) | ||
| Pila Pharma AB is a clinical stage pharmaceutical company. It is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent. | $0 | -40% | $8M | $8M | 62.0x | (4.4x) | ||
| ODI Pharma AB is a provider of medicinal cannabis. It offers its products to pharmacies, specialty clinics, and hospitals. | $0 | +91% | $8M | $7M | 21.2x | (12.8x) | ||
| Chosa Oncology AB is a biotechnology company engaged in the research and development in immunotherapy on therapeutic cancer vaccines. | $0 | +14% | $7M | $6M | — | (9.7x) | ||
| Modus Therapeutics Holding AB is a Swedish clinical biotechnology company developing a treatment for sepsis, endotoxemia, severe malaria, and other disorders with severe systemic inflammation, as well as states of anemia related to chronic inflammation, such as kidney diseases, through its patented polysaccharide, sevuparin. The drug candidate sevuparin has the opportunity to benefit patients and save large healthcare costs. | $0 | -27% | $7M | $5M | — | (2.6x) | ||
| Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets. | $0 | -49% | $4M | $3M | 1.0x | (1.9x) | ||
| Guard Therapeutics International AB is engaged in developing and commercializing the lead drug candidate ROSgard, and thereby contribute to the better and less harmful treatment of acute kidney injuries. | $0 | -93% | $3M | ($2M) | — | 0.1x | ||
| Double Bond Pharmaceutical International AB is a pharmaceutical company. The company develops and commercializes approaches for the treatment of cancers, infections, autoimmune diseases, and other life-threatening disorders. | $0 | -55% | $3M | $3M | 296.2x | (1357.9x) | ||
| Biosergen AB is a clinical stage biotechnology company advancing the treatment of life-threatening fungal infections. Biosergen’ s mission is to develop the drug candidate BSG005 into a superior antifungal therapy with broader efficacy and improved safety over existing treatments. BSG005 potential is to eliminate fungal infections rather than just slowing their growth, reducing the risk of resistance. | $1 | -82% | $2M | $796K | — | (0.2x) | ||
| Gabather AB is engaged in developing novel drugs to treat several diseases originating in the central nervous system. It has four main focus areas anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as cognition-enhancing treatments, including for Alzheimer's disease. | $0 | +2% | $2M | $2M | — | (3.9x) | ||
| Respiratorius AB develops pharmaceutical drugs to treat the common diseases namely Cancer, Chronic Obstructive Pulmonary Disease (COPD), and asthma as well as better methods for diagnosing cardiovascular diseases. The company's drug candidates includes RCD405, VAL001, RESP2000, RESP3000, RESP9000, and RESP1000. | $0 | -62% | $2M | $2M | — | (5.4x) | ||
| Aptahem AB develops aptamer-based drugs for the treatment of acute life-threatening conditions where coagulation and inflammation interact in the disease process. The company's main candidate Apta-1 is developed as an emergency medicine intended to prevent the occurrence of life-threatening organ and tissue damage in patients suffering from sepsis. | $0 | -39% | $2M | $1M | — | (2.2x) | ||
| ExpreS2ion Biotech Holding AB is a biotechnology company that develops vaccines. It has developed a human clinical Phase III-validated technology platform, ExpreS2, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Its product pipeline comprises ES2B-C001, a HER2-VLP-based vaccine in development for human breast cancer therapy; ES2B-I002, a Cytomegalovirus (CMV) vaccine; and several exploratory vaccine projects targeting pathways validated by commercial monoclonal antibody products. Geographically, the company operates in the Nordics region and also has a presence in other countries. | $0 | -92% | $2M | ($3M) | (8.1x) | 0.7x | ||
| Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center. | $0 | -51% | $2M | $2M | — | (2.2x) | ||
| Nidhogg Resources Holding AB is a Company operates in the mining sector. The company is a Swedish-owned company with a focus on extracting raw materials in Sweden and the USA. The company's plan of action is to build on existing infrastructure, apply new technology/innovations to support and drive the energy system transition. | $0 | -91% | $492K | $389K | — | (1.2x) | ||
| PharmaLundensis AB is a Sweden based drug manufacturing company, The company focuses on the development and marketing of pharmaceuticals. It is engaged in developing drugs for the lung diseases, such as chronic obstructive pulmonary disease and asthma, as well as drugs for mercury toxicology. | $0 | -88% | $428K | $810K | — | (1.3x) | ||
| Lidds AB is a Sweden-based drug delivery company focused on its proprietary NanoZolid technology platform. The NanoZolid system is used to formulate drugs for local administration with controlled and sustained release over extended periods. The company offers this technology to partners and is also developing its own pipeline of drug candidates, prominently in oncology, where the platform is used to enable localized and sustained drug delivery. It has a pipeline with several projects in clinical development, both in early- and late-stage clinical phases, and projects about to enter clinical development. | $0 | -- | $371K | ($839K) | — | — | ||
| QUIA PHARMA AB is a development company for pharmaceuticals based on a patented drug delivery platform, Uni-Qleaver. The company develops improved and patentable forms of drugs under development or already approved by pharmaceutical authorities. These refined and enhanced forms of medicine are based on the Company's exceptional and patented technology platform. In addition to this, the Company offers multinational sales of omega-3, astaxin and collagen through Amazon. | $0 | -- | $305K | $304K | — | — | ||
| Lipigon Pharmaceuticals AB develops medicines for diseases caused by disorders of the body's handling of fats. It focuses on orphan drugs for unusual diseases where there is no adequate treatment. | $0 | -97% | $173K | ($908K) | — | — | ||
| Median | $0 | -20% | $20M | $18M | 16.8x | (4.4x) |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Recent Insights
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.